## Steffen Thiel

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4701877/publications.pdf

Version: 2024-02-01

7672 15253 21,575 342 79 130 citations h-index g-index papers 359 359 359 12630 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	M-ficolin: a valuable biomarker to identify leukaemia from juvenile idiopathic arthritis. Archives of Disease in Childhood, 2022, 107, 371-376.	1.0	1
2	Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases. Journal of Clinical and Translational Hepatology, 2022, 10, 796-802.	0.7	3
3	Potency measurements of the complement system facilitated by antibodies targeting the zymogen form of complement factor D (Adipsin). Molecular Immunology, 2022, 146, 46-49.	1.0	2
4	Quantification of the pro-form of human complement component factor D (adipsin). Journal of Immunological Methods, 2022, 507, 113295.	0.6	1
5	A low level of naturally occurring antibodies associates with functional antibody deficiency. Clinical Immunology, 2022, 241, 109070.	1.4	2
6	Effect of dipeptidyl peptidaseâ€4 inhibitors on complement activation. Diabetes/Metabolism Research and Reviews, 2021, 37, e3385.	1.7	4
7	The level of naturally occurring antiâ€Î±Gal antibody predicts antibody response to polysaccharide vaccination in HIVâ€infected adults. Scandinavian Journal of Immunology, 2021, 93, e13008.	1.3	1
8	The human natural antiâ€Î±Gal antibody targets common pathogens by broadâ€spectrum polyreactivity. Immunology, 2021, 162, 434-451.	2.0	9
9	ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism. Science Advances, 2021, 7, .	4.7	22
10	The pattern-recognition molecule H-ficolin in relation to diabetic kidney disease, mortality, and cardiovascular events in type 1 diabetes. Scientific Reports, 2021, 11, 8919.	1.6	4
11	Proteolysis and inflammation of the kidney glomerulus. Cell and Tissue Research, 2021, 385, 489-500.	1.5	4
12	Plasma Lectin Pathway Complement Proteins in Patients With COVID-19 and Renal Disease. Frontiers in Immunology, 2021, 12, 671052.	2.2	8
13	Mannose-binding lectin and risk of infections in type 2 diabetes: A Danish cohort study. Journal of Diabetes and Its Complications, 2021, 35, 107873.	1.2	1
14	Protease inhibitor plasma concentrations associate with COVID-19 infection. Oxford Open Immunology, 2021, 2, iqab014.	1.2	7
15	Characterization of DNA–protein complexes by nanoparticle tracking analysis and their association with systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	7
16	Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity. Journal of Neuroinflammation, 2021, 18, 177.	3.1	18
17	The complement lectin pathway protein MAp19 and out-of-hospital cardiac arrest: Insights from two randomized clinical trials. European Heart Journal: Acute Cardiovascular Care, 2020, 9, S145-S152.	0.4	7
18	A Complement C3–Specific Nanobody for Modulation of the Alternative Cascade Identifies the C-Terminal Domain of C3b as Functional in C5 Convertase Activity. Journal of Immunology, 2020, 205, 2287-2300.	0.4	9

#	Article	IF	Citations
19	Complement activation in human autoimmune diseases and mouse models; employing a sandwich immunoassay specific for C3dg. Journal of Immunological Methods, 2020, 486, 112866.	0.6	10
20	Association between severe diabetic retinopathy and lectin pathway proteins – an 18-year follow-up study with newly diagnosed type 1 diabetes patients. Immunobiology, 2020, 225, 151939.	0.8	3
21	An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase. Journal of Immunology, 2020, 205, 1678-1694.	0.4	12
22	Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System. Frontiers in Immunology, 2020, 11, 1504.	2.2	17
23	Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans. Frontiers in Immunology, 2020, 11, 774.	2.2	5
24	Classical and lectin complement pathways and markers of inflammation for investigation of susceptibility to infections among healthy older adults. Immunity and Ageing, 2020, 17, 18.	1.8	8
25	Abundant human anti-Gall±3Gal antibodies display broad pathogen reactivity. Scientific Reports, 2020, 10, 4611.	1.6	19
26	Key Components of the Complement Lectin Pathway Are Not Only Required for the Development of Inflammatory Arthritis but Also Regulate the Transcription of Factor D. Frontiers in Immunology, 2020, 11, 201.	2.2	10
27	A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system. Journal of Biological Chemistry, 2020, 295, 8746-8758.	1.6	18
28	Associations of ficolins and mannose-binding lectin with acute myeloid leukaemia in adults. Scientific Reports, 2020, 10, 10561.	1.6	15
29	Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement. Molecular Immunology, 2020, 124, 200-210.	1.0	10
30	Complement activation by human IgG antibodies to galactoseâ€ <i>α</i> â€1,3â€galactose. Immunology, 2020, 1 66-79.	l 61 2.b	13
31	Proteins of the Lectin Pathway of complement activation at the site of injury in subarachnoid hemorrhage compared with peripheral blood. Brain and Behavior, 2020, 10, e01728.	1.0	5
32	Mannose-Binding Lectin and Risk of Cardiovascular Events and Mortality in Type 2 Diabetes: A Danish Cohort Study. Diabetes Care, 2020, 43, 2190-2198.	4.3	18
33	Selected factors of the innate immunity in Polish patients suffering from pulmonary tuberculosis. Immunobiology, 2020, 225, 151905.	0.8	4
34	Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations. Frontiers in Immunology, 2020, 10, 3097.	2.2	14
35	Adding MASP1 to the lectin pathwayâ€"Leprosy association puzzle: Hints from gene polymorphisms and protein levels. PLoS Neglected Tropical Diseases, 2020, 14, e0007534.	1.3	7
36	Remote ischemic preconditioning does not influence lectin pathway protein levels in head and neck cancer patients undergoing surgery. PLoS ONE, 2020, 15, e0230411.	1.1	2

#	Article	IF	CITATIONS
37	Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors. Frontiers in Immunology, 2020, 11, 574457.	2.2	4
38	Pattern Recognition Molecules of the Lectin Pathwayâ€"Screening of Patients with Suspected Immunodeficiency. Journal of Clinical Immunology, 2019, 39, 668-677.	2.0	7
39	Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. Frontiers in Immunology, 2019, 10, 2007.	2.2	47
40	Complement lectin pathway protein levels reflect disease activity in juvenile idiopathic arthritis: a longitudinal study of the Nordic JIA cohort. Pediatric Rheumatology, 2019, 17, 63.	0.9	3
41	Lectin pathway proteins of the complement system in normotensive pregnancy and preâ€eclampsia. American Journal of Reproductive Immunology, 2019, 81, e13092.	1.2	7
42	Effect of long-term remote ischemic conditioning on inflammation and cardiac remodeling. Scandinavian Cardiovascular Journal, 2019, 53, 183-191.	0.4	11
43	Circulating lectin pathway proteins do not predict short-term cardiac outcomes after myocardial infarction. Clinical and Experimental Immunology, 2019, 198, 94-100.	1.1	6
44	Ficolin-3 Deficiency Is Associated with Disease and an Increased Risk of Systemic Lupus Erythematosus. Journal of Clinical Immunology, 2019, 39, 421-429.	2.0	28
45	Reduced Mannose-Binding Lectin-Associated Serine Protease (MASP)-1 is Associated with Disturbed Coagulation in Septic Shock. Thrombosis and Haemostasis, 2019, 119, 952-961.	1.8	16
46	Factors involved in initiation and regulation of complement lectin pathway influence postoperative outcome after pediatric cardiac surgery involving cardiopulmonary bypass. Scientific Reports, 2019, 9, 2930.	1.6	7
47	Changes in the Lectin Pathway Following Intracerebral or Spontaneous Subarachnoid Hemorrhage. Molecular Neurobiology, 2019, 56, 78-87.	1.9	14
48	Plasma levels of H- and L-ficolin are increased in axial spondyloarthritis: improvement of disease identification. Clinical and Experimental Immunology, 2019, 199, 79-87.	1.1	9
49	Antibody Dependent Enhancement of Infections after High Dose Chemotherapy. Blood, 2019, 134, 1047-1047.	0.6	2
50	A potent complement factor C3–specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement. Journal of Biological Chemistry, 2018, 293, 6269-6281.	1.6	47
51	Models of the complement C1 complex. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3866-E3866.	3.3	3
52	The lectin pathway and coagulation in lung cancer patients undergoing lobectomy – A randomised controlled trial. Thrombosis Research, 2018, 163, 92-99.	0.8	5
53	Progressive IgA Nephropathy Is Associated With Low Circulating Mannan-Binding Lectin–Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H–Related Protein-5 (FHR5) Deposition. Kidney International Reports, 2018, 3, 426-438.	0.4	57
54	Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine. BMJ Open, 2018, 8, e018166.	0.8	15

#	Article	IF	Citations
55	A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein. Frontiers in Immunology, 2018, 9, 2822.	2.2	7
56	MASP-1 and MASP-2 Serum Levels Are Associated With Worse Prognostic in Cervical Cancer Progression. Frontiers in Immunology, 2018, 9, 2742.	2.2	20
57	The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT). Frontiers in Immunology, 2018, 9, 2153.	2.2	15
58	Ficolin-1 and Ficolin-3 Plasma Levels Are Altered in HIV and HIV/HCV Coinfected Patients From Southern Brazil. Frontiers in Immunology, 2018, 9, 2292.	2.2	15
59	The complement lectin pathway after cardiac arrest. Scandinavian Journal of Immunology, 2018, 88, e12680.	1.3	4
60	MASP-1., 2018,, 69-78.		0
61	MASP-2. , 2018, , 79-87.		1
62	MASP-3., 2018,, 89-97.		0
63	The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 581.	2.2	32
64	The Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 1136-1144.	1.0	36
65	Targeting of Liver Mannan-Binding Lectin–Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis. ImmunoHorizons, 2018, 2, 274-295.	0.8	16
66	Collectin Liver 1 and Collectin Kidney 1 of the Lectin Complement Pathway Are Associated With Mortality After Kidney Transplantation. American Journal of Transplantation, 2017, 17, 265-271.	2.6	12
67	Structure and activation of C1, the complex initiating the classical pathway of the complement cascade. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 986-991.	3.3	80
68	M-ficolin is present in <i>Aspergillus fumigatus</i> infected lung and modulates epithelial cell immune responses elicited by fungal cell wall polysaccharides. Virulence, 2017, 8, 1870-1879.	1.8	29
69	Functional and structural insight into properdin control of complement alternative pathway amplification. EMBO Journal, 2017, 36, 1084-1099.	3.5	69
70	Endogenous Natural Complement Inhibitor Regulates Cardiac Development. Journal of Immunology, 2017, 198, 3118-3126.	0.4	11
71	Incident microalbuminuria and complement factor mannanâ€binding lectinâ€associated protein 19 in people with newly diagnosed type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2895.	1.7	6
72	Plasma levels of MASP-1, MASP-3 and MAp44 in patients with type 2 diabetes: influence of glycaemic control, body composition and polymorphisms in the <i>MASP1</i> gene. Clinical and Experimental Immunology, 2017, 189, 103-112.	1.1	17

#	Article	IF	CITATIONS
73	Lectin complement pathway proteins in healthy individuals. Clinical and Experimental Immunology, 2017, 188, 138-147.	1.1	80
74	Analysis of Factor D Isoforms in Malpuech–Michels–Mingarelli–Carnevale Patients Highlights the Role of MASP-3 as a Maturase in the Alternative Pathway of Complement. Journal of Immunology, 2017, 199, 2158-2170.	0.4	43
75	Reply to Arlaud et al.: Structure of the C1 complex and the unbound C1r2s2 tetramer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5768-E5770.	3.3	1
76	Ficolin-1 Levels in Patients Developing Vasospasm and Cerebral Ischemia After Spontaneous Subarachnoid Hemorrhage. Molecular Neurobiology, 2017, 54, 6572-6580.	1.9	14
77	Collectins, H-ficolin and LL-37 reduce influence viral replication in human monocytes and modulate virus-induced cytokine production. Innate Immunity, 2017, 23, 77-88.	1.1	21
78	A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine. Nutrients, 2017, 9, 499.	1.7	24
79	Extensive Basal Level Activation of Complement Mannose-Binding Lectin-Associated Serine Protease-3: Kinetic Modeling of Lectin Pathway Activation Provides Possible Mechanism. Frontiers in Immunology, 2017, 8, 1821.	2.2	20
80	Global Autorecognition and Activation of Complement by Mannan-Binding Lectin in a Mouse Model of Type 1 Diabetes. Mediators of Inflammation, 2017, 2017, 1-13.	1.4	8
81	Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes. Journal of Diabetes Research, 2017, 2017, 1-4.	1.0	1
82	Diabetes Is Associated with Increased Autoreactivity of Mannan-Binding Lectin. Journal of Diabetes Research, 2017, 2017, 1-12.	1.0	171
83	Increased Autoreactivity of the Complement-Activating Molecule Mannan-Binding Lectin in a Type 1 Diabetes Model. Journal of Diabetes Research, 2016, 2016, 1-7.	1.0	19
84	Oligomerization of Mannanâ€binding Lectin Dictates Binding Properties and Complement Activation. Scandinavian Journal of Immunology, 2016, 84, 12-19.	1.3	28
85	Influence of mannan-binding lectin and MAp44 on outcome in comatose survivors of out-of-hospital cardiac arrest. Resuscitation, 2016, 101, 27-34.	1.3	3
86	Distinct Longitudinal Associations of MBL, MASP-1, MASP-2, MASP-3, and MAp44 With Endothelial Dysfunction and Intima–Media Thickness. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1278-1285.	1,1	17
87	The pattern recognition molecule collectin-L1 in critically ill children. Pediatric Research, 2016, 80, 237-243.	1.1	5
88	Mannan-Binding Lectin–Associated Serine Protease 1/3 Cleavage of Pro–Factor D into Factor D In Vivo and Attenuation of Collagen Antibody-Induced Arthritis through Their Targeted Inhibition by RNA Interference–Mediated Gene Silencing. Journal of Immunology, 2016, 197, 3680-3694.	0.4	15
89	Low level of MAp44, an inhibitor of the lectin complement pathway, and long-term graft and patient survival; a cohort study of 382 kidney recipients. BMC Nephrology, 2016, 17, 148.	0.8	11
90	Association of lectin pathway proteins with intra-abdominal Candida infection in high-risk surgical intensive-care unit patients. A prospective cohort study within the fungal infection network of Switzerland. Journal of Infection, 2016, 72, 377-385.	1.7	6

#	Article	IF	Citations
91	Complement activation, regulation, and molecular basis for complementâ€related diseases. EMBO Journal, 2015, 34, 2735-2757.	3.5	302
92	Novel MASP1 mutations are associated with an expanded phenotype in 3MC1 syndrome. Orphanet Journal of Rare Diseases, 2015, 10, 128.	1.2	46
93	Collectin liver 1 and collectin kidney 1 and other complement-associated pattern recognition molecules in systemic lupus erythematosus. Clinical and Experimental Immunology, 2015, 182, 132-138.	1.1	32
94	High Ficolin-3 Level at the Time of Transplantation Is an Independent Risk Factor for Graft Loss in Kidney Transplant Recipients. Transplantation, 2015, 99, 791-796.	0.5	21
95	Ficolin B in Diabetic Kidney Disease in a Mouse Model of Type 1 Diabetes. Mediators of Inflammation, 2015, 2015, 1-6.	1.4	7
96	Structural Insights into the Initiating Complex of the Lectin Pathway of Complement Activation. Structure, 2015, 23, 342-351.	1.6	48
97	Plasma levels of mannan-binding lectin-associated serine proteases MASP-1 and MASP-2 are elevated in type 1 diabetes and correlate with glycaemic control. Clinical and Experimental Immunology, 2015, 180, 227-232.	1.1	43
98	Evaluation of complement proteins as screening markers for colorectal cancer. Cancer Immunology, Immunotherapy, 2015, 64, 41-50.	2.0	16
99	Levels in Plasma of the Serine Proteases and Associated Proteins of the Lectin Pathway Are Altered in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2015, 42, 948-951.	1.0	19
100	Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study. Diabetes Care, 2015, 38, 1898-1903.	4.3	22
101	Investigation of Complement-activating Pattern Recognition Molecules and Associated Enzymes as Possible Inflammatory Markers in Oligoarticular and Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2015, 42, 1252-1258.	1.0	10
102	Circulating mannanâ€binding lectin, Mâ€, Lâ€, Hâ€ficolin and collectinâ€liverâ€1 levels in patients with acute liver failure. Liver International, 2015, 35, 756-763.	1.9	20
103	Genetic Variation of COLEC10 and COLEC11 and Association with Serum Levels of Collectin Liver 1 (CL-L1) and Collectin Kidney 1 (CL-K1). PLoS ONE, 2015, 10, e0114883.	1.1	31
104	Complement activation by ligand-driven juxtaposition of discrete pattern recognition complexes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13445-13450.	3.3	63
105	Cystic Fibrosis Sputum DNA Has NETosis Characteristics and Neutrophil Extracellular Trap Release Is Regulated by Macrophage Migration-Inhibitory Factor. Journal of Innate Immunity, 2014, 6, 765-779.	1.8	170
106	Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 3-9.	0.4	11
107	Serum MASP-1 in complex with MBL activates endothelial cells. Molecular Immunology, 2014, 59, 39-45.	1.0	30
108	Lectin pathway of complement activation and relation with clinical complications in critically ill children. Pediatric Research, 2014, 75, 99-108.	1.1	27

#	Article	IF	CITATIONS
109	Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18Âyear follow-up study. Diabetologia, 2014, 57, 2201-2207.	2.9	24
110	Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study. American Journal of Gastroenterology, 2014, 109, 1749-1756.	0.2	81
111	Essential Role for the Lectin Pathway in Collagen Antibody–Induced Arthritis Revealed through Use of Adenovirus Programming Complement Inhibitor MAp44 Expression. Journal of Immunology, 2014, 193, 2455-2468.	0.4	37
112	The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF-α therapy. Journal of Crohn's and Colitis, 2014, 8, 521-528.	0.6	9
113	The Pro-Factor D Cleaving Activity of MASP-1/-3 Is Not Required for Alternative Pathway Function. Journal of Immunology, 2014, 192, 5447-5448.	0.4	8
114	Bipolar and panic disorders may be associated with hereditary defects in the innate immune system. Journal of Affective Disorders, 2014, 164, 148-154.	2.0	36
115	Changes in the Levels of Mannan-Binding Lectin and Ficolins During Head-Down Tilted Bed Rest. Aviation, Space, and Environmental Medicine, 2014, 85, 805-811.	0.6	1
116	Assay for Estimation of the Functional Activity of the Mannan-Binding Lectin Pathway of the Complement System. Methods in Molecular Biology, 2014, 1100, 131-139.	0.4	3
117	Susceptibility to Leprosy is Associated with M-ficolin Polymorphisms. Journal of Clinical Immunology, 2013, 33, 210-219.	2.0	43
118	Toward a structure-based comprehension of the lectin pathway of complement. Molecular Immunology, 2013, 56, 413-422.	1.0	83
119	Humoral Pattern Recognition and the Complement System. Scandinavian Journal of Immunology, 2013, 78, 181-193.	1.3	122
120	Toward a structure-based comprehension of the lectin pathway of complement. Molecular Immunology, 2013, 56, 222-231.	1.0	67
121	Mitochondria and the Lectin Pathway of Complement. Journal of Biological Chemistry, 2013, 288, 8016-8027.	1.6	36
122	Recombinant expression of the autocatalytic complement protease MASP-1 is crucially dependent on co-expression with its inhibitor, C1 inhibitor. Protein Expression and Purification, 2013, 88, 173-182.	0.6	7
123	Co-Complexes of MASP-1 and MASP-2 Associated with the Soluble Pattern-Recognition Molecules Drive Lectin Pathway Activation in a Manner Inhibitable by MAp44. Journal of Immunology, 2013, 191, 1334-1345.	0.4	48
124	Good agreement between capillary and venous sampling for lectin pathway proteins. Immunobiology, 2013, 218, 465-469.	0.8	2
125	Protein–fatty acid complexes: biochemistry, biophysics and function. FEBS Journal, 2013, 280, 1733-1749.	2.2	44
126	Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases. Clinical and Experimental Immunology, 2013, 173, 112-120.	1.1	46

#	Article	IF	Citations
127	The cytotoxicity of fatty acid/αâ€lactalbumin complexes depends on the amount and type of fatty acid. European Journal of Lipid Science and Technology, 2013, 115, 591-600.	1.0	19
128	Brief Report: Mâ€Ficolin Levels Reflect Disease Activity and Predict Remission in Early Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 3045-3050.	6.7	22
129	Investigations on Collectin Liver 1. Journal of Biological Chemistry, 2013, 288, 23407-23420.	1.6	69
130	Response to Comment on "Mannan-Binding Lectin-Associated Serine Protease (MASP)-1 Is Crucial for Lectin Pathway Activation in Human Serum, whereas neither MASP-1 nor MASP-3 Is Required for Alternative Pathway Function― Journal of Immunology, 2013, 190, 2477.2-2478.	0.4	4
131	Diabetesâ€induced Changes in Mannanâ€binding Lectin Levels and Complement Activation in a Mouse Model of Type 1 Diabetes. Scandinavian Journal of Immunology, 2013, 77, 187-194.	1.3	30
132	M-Ficolin Binds Selectively to the Capsular Polysaccharides of Streptococcus pneumoniae Serotypes 19B and 19C and of a Streptococcus mitis Strain. Infection and Immunity, 2013, 81, 452-459.	1.0	31
133	Oxidative Stress Sensitizes Retinal Pigmented Epithelial (RPE) Cells to Complement-mediated Injury in a Natural Antibody-, Lectin Pathway-, and Phospholipid Epitope-dependent Manner. Journal of Biological Chemistry, 2013, 288, 12753-12765.	1.6	55
134	Leprosy Association with Low MASP-2 Levels Generated by MASP2 Haplotypes and Polymorphisms Flanking MAp19 Exon 5. PLoS ONE, 2013, 8, e69054.	1.1	30
135	Low Levels of Mannan-Binding Lectin or Ficolins Are Not Associated with an Increased Risk of Cytomegalovirus Disease in HIV-Infected Patients. PLoS ONE, 2013, 8, e51983.	1.1	8
136	Polymorphisms in the MASP1 Gene Are Associated with Serum Levels of MASP-1, MASP-3, and MAp44. PLoS ONE, 2013, 8, e73317.	1.1	26
137	Mannan-Binding Lectin in Diabetic Kidney Disease: The Impact of Mouse Genetics in a Type 1 Diabetes Model. Experimental Diabetes Research, 2012, 2012, 1-9.	3.8	19
138	The Effect of Weight Loss on Serum Mannose-Binding Lectin Levels. Clinical and Developmental Immunology, 2012, 2012, 1-5.	3.3	4
139	MAPK phosphatase-1 is required for regulatory natural autoantibody-mediated inhibition of TLR responses. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19745-19750.	3.3	33
140	Structural basis for activation of the complement system by component C4 cleavage. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15425-15430.	3.3	115
141	Complement Activation and Prognosis in Patients With Type 2 Diabetes and Myocardial Infarction. Diabetes Care, 2012, 35, 911-917.	4.3	51
142	The Role of Nanometer-Scaled Ligand Patterns in Polyvalent Binding by Large Mannan-Binding Lectin Oligomers. Journal of Immunology, 2012, 188, 1292-1306.	0.4	39
143	M-ficolin concentrations in cord blood are related to circulating phagocytes and to early-onset sepsis. Pediatric Research, 2012, 71, 368-374.	1.1	14
144	Human H-Ficolin Inhibits Replication of Seasonal and Pandemic Influenza A Viruses. Journal of Immunology, 2012, 189, 2478-2487.	0.4	57

#	Article	IF	CITATIONS
145	Studies of the Pattern Recognition Molecule H-ficolin. Journal of Biological Chemistry, 2012, 287, 8071-8081.	1.6	32
146	The salivary scavenger and agglutinin binds MBL and regulates the lectin pathway of complement in solution and on surfaces. Frontiers in Immunology, 2012, 3, 205.	2.2	29
147	Mannan-Binding Lectin-Associated Serine Protease (MASP)-1 Is Crucial for Lectin Pathway Activation in Human Serum, whereas neither MASP-1 nor MASP-3 Is Required for Alternative Pathway Function. Journal of Immunology, 2012, 189, 3957-3969.	0.4	142
148	Effects of interferon-beta therapy on elements in the antiviral immune response towards the human herpesviruses EBV, HSV, and VZV, and to the human endogenous retroviruses HERV-H and HERV-W in multiple sclerosis. Journal of Neuroimmunology, 2012, 249, 105-108.	1.1	24
149	Levels of lectin pathway proteins in plasma and synovial fluid of rheumatoid arthritis and osteoarthritis. Rheumatology International, 2012, 32, 1457-1463.	1.5	43
150	M-ficolin levels are associated with the occurrence of severe infections in patients with haematological cancer undergoing chemotherapy. Clinical and Experimental Immunology, 2012, 167, 303-308.	1.1	16
151	MBL and MASP-2 concentrations in serum and MBL2 promoter polymorphisms are associated to schizophrenia. Acta Neuropsychiatrica, 2012, 24, 199-207.	1.0	11
152	Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components. Clinical and Experimental Immunology, 2012, 169, 38-48.	1.1	70
153	Non-Synonymous Polymorphisms in the FCN1 Gene Determine Ligand-Binding Ability and Serum Levels of M-Ficolin. PLoS ONE, 2012, 7, e50585.	1.1	27
154	M-ficolin in children with cancer. Immunobiology, 2011, 216, 633-638.	0.8	12
155	Multiplex sequence-specific polymerase chain reaction reveals new MASP2 haplotypes associated with MASP-2 and MAp19 serum levels. Human Immunology, 2011, 72, 753-760.	1.2	23
156	Preparation and comparison of cytotoxic complexes formed between oleic acid and either bovine or human α-lactalbumin. Journal of Dairy Science, 2011, 94, 2159-2170.	1.4	36
157	Serum concentrations of lectinâ€pathway components in healthy neonates, children and adults: mannanâ€binding lectin (MBL), M― L― and Hâ€ficolin, and MBLâ€associated serine proteaseâ€2 (MASPâ€2). PAllergy and Immunology, 2011, 22, 424-430.	'e <b>rli</b> atric	93
158	Mannanâ€Binding Lectin (MBL) and MBLâ€Associated Serine Protease 2 (MASPâ€2) Genotypes in Colorectal Cancer. Scandinavian Journal of Immunology, 2011, 73, 122-127.	1.3	26
159	The toxicity of bovine αâ€lactalbumin made lethal to tumor cells is highly dependent on oleic acid and induces killing in cancer cell lines and noncancerâ€derived primary cells. FEBS Journal, 2011, 278, 1955-1967.	2.2	75
160	The role of higher-order protein structure in supporting binding by heteroclitic monoclonal antibodies: The monoclonal antibody KIM185 to CD18 also binds C4-binding protein. Molecular Immunology, 2011, 49, 38-47.	1.0	4
161	Assay interference caused by antibodies reacting with rat kappa light-chain in human sera. Journal of Immunological Methods, 2011, 372, 204-208.	0.6	16
162	Biological variation of anti- $\hat{l}\pm$ Gal-antibodies studied by a novel Time-Resolved ImmunoFluorometric Assay. Journal of Immunological Methods, 2011, 373, 26-35.	0.6	20

#	Article	IF	Citations
163	MAp19, the alternative splice product of the MASP2 gene. Journal of Immunological Methods, 2011, 373, 89-101.	0.6	65
164	Disease-Causing Mutations in Genes of the Complement System. American Journal of Human Genetics, 2011, 88, 689-705.	2.6	157
165	Congenital H-ficolin deficiency in premature infants with severe necrotising enterocolitis. Gut, 2011, 60, 1438-1439.	6.1	52
166	Investigations on the pattern recognition molecule M-ficolin: quantitative aspects of bacterial binding and leukocyte association. Journal of Leukocyte Biology, 2011, 90, 425-437.	1.5	44
167	Comment on: Lin et al. (2010) Immune Cell–Derived C3 Is Required for Autoimmune Diabetes Induced by Multiple Low Doses of Streptozotocin. Diabetes;59: 2247–2252: FIG. 1 Diabetes, 2011, 60, e7-e8.	0.3	5
168	Efficacy of Recombinant Human Mannose Binding Lectin Alone and in Combination with Itraconazole Against Murine <i>Candida albicans </i>	1.0	8
169	Biological variations of MASP-3 and MAp44, two splice products of the MASP1 gene involved in regulation of the complement system. Journal of Immunological Methods, 2010, 361, 37-50.	0.6	88
170	Lack of the pattern recognition molecule mannose-binding lectin increases susceptibility to influenza A virus infection. BMC Immunology, 2010, 11, 64.	0.9	70
171	Shedding of Large Functionally Active CD11/CD18 Integrin Complexes from Leukocyte Membranes during Synovial Inflammation Distinguishes Three Types of Arthritis through Differential Epitope Exposure. Journal of Immunology, 2010, 185, 4154-4168.	0.4	45
172	Characteristics and Biological Variations of M-Ficolin, a Pattern Recognition Molecule, in Plasma. Journal of Innate Immunity, 2010, 2, 167-180.	1.8	105
173	Mannan-binding lectin in women with a history of recurrent vulvovaginal candidiasis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 148, 163-165.	0.5	18
174	Differential Role of the Lectin Pathway of Complement Activation in Susceptibility to Neonatal Sepsis. Clinical Infectious Diseases, 2010, 51, 153-162.	2.9	59
175	MAp44, a Human Protein Associated with Pattern Recognition Molecules of the Complement System and Regulating the Lectin Pathway of Complement Activation. Journal of Immunology, 2009, 183, 7371-7378.	0.4	164
176	Polymorphisms in Mannan-Binding Lectin (MBL)-Associated Serine Protease 2 Affect Stability, Binding to MBL, and Enzymatic Activity. Journal of Immunology, 2009, 182, 2939-2947.	0.4	65
177	Local Inflammation Induces Complement Crosstalk Which Amplifies the Antimicrobial Response. PLoS Pathogens, 2009, 5, e1000282.	2.1	85
178	Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis. Journal of Neuroimmunology, 2009, 215, 108-116.	1.1	28
179	Mannanâ€binding lectin deficiency modulates the humoral immune response dependent on the genetic environment. Immunology, 2009, 127, 279-288.	2.0	33
180	M-ficolin in the neonatal period: Associations with need for mechanical ventilation and mortality in premature infants with necrotising enterocolitis. Molecular Immunology, 2009, 46, 2597-2603.	1.0	26

#	Article	IF	Citations
181	Humoral Pattern Recognition Molecules: Mannan-Binding Lectin and Ficolins. Advances in Experimental Medicine and Biology, 2009, 653, 58-73.	0.8	65
182	Regulation of Dendritic Cells and Macrophages by an Anti-Apoptotic Cell Natural Antibody that Suppresses TLR Responses and Inhibits Inflammatory Arthritis. Journal of Immunology, 2009, 183, 1346-1359.	0.4	158
183	Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit*. Critical Care Medicine, 2009, 37, 192-e3.	0.4	130
184	Mannan-Binding Lectin Inhibits Humoural Responses. Scandinavian Journal of Immunology, 2008, 59, 626-626.	1.3	0
185	The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clinical and Experimental Immunology, 2008, 90, 31-35.	1.1	240
186	Gene frequency and partial protein characterization of an allelic variant of mannan binding protein associated with low serum concentrations. Clinical and Experimental Immunology, 2008, 90, 517-521.	1.1	115
187	Mannan-binding proteinâ€"levels in plasma and upper-airways secretions and frequency of genotypes in children with recurrence of otitis media. Clinical and Experimental Immunology, 2008, 94, 99-104.	1.1	59
188	Binding of mannan-binding protein to various bacterial pathogens of meningitis. Clinical and Experimental Immunology, 2008, 97, 411-416.	1.1	95
189	The level of the serum opsonin, mannan-binding protein in HIV-1 antibody-positive patients. Clinical and Experimental Immunology, 2008, 100, 219-222.	1.1	77
190	An enzyme-linked immunosorbent assay (ELISA) for quantification of mouse surfactant protein D (SP-D). Journal of Immunological Methods, 2008, 330, 75-85.	0.6	22
191	Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2 —a prognostic marker in colorectal cancer. Human Immunology, 2008, 69, 414-420.	1.2	25
192	Binding and activation of human and mouse complement by Cryptosporidium parvum (Apicomplexa) and susceptibility of C1q- and MBL-deficient mice to infection. Molecular Immunology, 2008, 45, 3392-3400.	1.0	16
193	Increased susceptibility of complement factor B/C2 double knockout mice and mannan-binding lectin knockout mice to systemic infection with Candida albicans. Molecular Immunology, 2008, 45, 3934-3941.	1.0	39
194	Impact of the complement lectin pathway on cytomegalovirus disease early after kidney transplantation. Nephrology Dialysis Transplantation, 2008, 23, 4054-4060.	0.4	22
195	Conformational Changes in Mannan-Binding Lectin Bound to Ligand Surfaces. Journal of Immunology, 2007, 178, 3016-3022.	0.4	53
196	Cell Surface Detachment of Pregnancy-associated Plasma Protein-A Requires the Formation of Intermolecular Proteinase-Inhibitor Disulfide Bonds and Glycosaminoglycan Covalently Bound to the Inhibitor. Journal of Biological Chemistry, 2007, 282, 1769-1778.	1.6	18
197	Identification of the Site of Human Mannan-Binding Lectin Involved in the Interaction with Its Partner Serine Proteases: The Essential Role of Lys55. Journal of Immunology, 2007, 178, 5710-5716.	0.4	55
198	Genetic polymorphisms of mannan binding lectin (MBL), serum levels of MBL, the MBL associated serine protease and H-ficolin in patients with Crohn's disease. Gut, 2007, 56, 311-312.	6.1	16

#	Article	IF	Citations
199	New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology, 2007, 212, 301-311.	0.8	52
200	Complement protein C1q induces maturation of human dendritic cells. Molecular Immunology, 2007, 44, 3389-3397.	1.0	76
201	Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Molecular Immunology, 2007, 44, 3875-3888.	1.0	234
202	Genetic influences on mannan-binding lectin (MBL) and mannan-binding lectin associated serine protease-2 (MASP-2) activity. Genetic Epidemiology, 2007, 31, 31-41.	0.6	20
203	C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO Journal, 2007, 26, 3431-3440.	<b>3.</b> 5	116
204	Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes and Immunity, 2007, 8, 154-163.	2.2	85
205	Burn Injury Reveals Altered Phenotype in Mannan-Binding Lectin-Deficient Mice. Journal of Investigative Dermatology, 2007, 127, 1524-1531.	0.3	33
206	Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. Clinical and Experimental Immunology, 2007, 148, 382-389.	1.1	82
207	Biological Variation in Circulating Levels of Mannanâ€Binding Lectin (MBL) and MBLâ€Associated Serine Proteaseâ€2 and the Influence of Age, Gender and Physical Exercise. Scandinavian Journal of Immunology, 2007, 66, 458-464.	1.3	63
208	Gene–environment interactions in multiple sclerosis: Innate and adaptive immune responses to human endogenous retrovirus and herpesvirus antigens and the lectin complement activation pathway. Journal of Neuroimmunology, 2007, 183, 175-188.	1.1	39
209	Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice. Diabetologia, 2007, 50, 1541-1549.	2.9	63
210	Clinical manifestations of mannan-binding lectin deficiency. Molecular Immunology, 2006, 43, 86-96.	1.0	190
211	Elevated levels of mannan-binding leptin (MBL) and eosinophilia in patients of bronchial asthma with allergic rhinitis and allergic bronchopulmonary aspergillosis associate with a novel intronic polymorphism in MBL. Clinical and Experimental Immunology, 2006, 143, 414-419.	1.1	73
212	Hormonal regulation of mannan-binding lectin synthesis in hepatocytes. Clinical and Experimental Immunology, 2006, 145, 173-182.	1.1	56
213	MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 555-560.	1.3	28
214	Influence of major surgery on the mannan-binding lectin pathway of innate immunity. Clinical and Experimental Immunology, 2006, 144, 239-246.	1.1	49
215	Phase I Safety, Tolerability, and Pharmacokinetic Study of Recombinant Human Mannan-Binding Lectin. Journal of Clinical Immunology, 2006, 26, 465-475.	2.0	86
216	Mannan-Binding lectin in asthma and allergy. Current Allergy and Asthma Reports, 2006, 6, 377-383.	2.4	17

#	Article	IF	CITATIONS
217	Chemotherapy-related infections in patients with multiple myeloma: associations with mannan-binding lectin genotypes. European Journal of Haematology, 2006, 77, 19-26.	1.1	37
218	The mannan-binding lectin pathway and lung disease in cystic fibrosis—dysfunction of mannan-binding lectin-associated serine protease 2 (MASP-2) may be a major modifier. Clinical Immunology, 2006, 121, 324-331.	1.4	57
219	Quantification of mannan-binding lectin. Journal of Immunological Methods, 2006, 315, 49-60.	0.6	33
220	Mannose-Binding Lectin and Mortality in Type 2 Diabetes. Archives of Internal Medicine, 2006, 166, 2007.	4.3	79
221	Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway. International Immunology, 2006, 19, 141-149.	1.8	81
222	Deficiency of Mannose-Binding Lectin Greatly Increases Susceptibility to Postburn Infection with <i>Pseudomonas aeruginosa </i>  i>. Journal of Immunology, 2006, 176, 1769-1775.	0.4	94
223	Activation of the Lectin Pathway by Natural IgM in a Model of Ischemia/Reperfusion Injury. Journal of Immunology, 2006, 177, 4727-4734.	0.4	139
224	Early Posttransplant Serum Osteoprotegerin Levels Predict Long-Term (8-Year) Patient Survival and Cardiovascular Death in Renal Transplant Patients. Journal of the American Society of Nephrology: JASN, 2006, 17, 1746-1754.	3.0	54
225	Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. Journal of Clinical Investigation, 2006, 116, 1425-1434.	3.9	163
226	Polymorphisms of MBL2, Encoding Mannan-Binding Lectin, Influences the Risk of Sepsis in Multiple Myeloma Patients during Autologous Stem Cell Transplantation (ASCT) Blood, 2006, 108, 5301-5301.	0.6	0
227	Mannan-Binding Lectin Recognizes Structures on Ischaemic Reperfused Mouse Kidneys and is Implicated in Tissue Injury. Scandinavian Journal of Immunology, 2005, 61, 426-434.	1.3	140
228	M-ficolin, an Innate Immune Defence Molecule, Binds Patterns of Acetyl Groups and Activates Complement. Scandinavian Journal of Immunology, 2005, 62, 462-473.	1.3	103
229	Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship. Clinical and Experimental Immunology, 2005, 139, 306-313.	1.1	70
230	Preoperative mannan-binding lectin pathway and prognosis in colorectal cancer. Cancer Immunology, Immunotherapy, 2005, 54, 265-272.	2.0	42
231	Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Seminars in Immunopathology, 2005, 27, 299-319.	4.0	114
232	Increased levels of mannan-binding lectin in type $1$ diabetic patients with incipient and overt nephropathy. Diabetologia, 2005, 48, 198-202.	2.9	85
233	Effect of Capsulation of Opportunistic Pathogenic Bacteria on Binding of the Pattern Recognition Molecules Mannan-Binding Lectin, L-Ficolin, and H-Ficolin. Infection and Immunity, 2005, 73, 1052-1060.	1.0	174
234	Role of collectins in innate immunity against aspergillosis. Medical Mycology, 2005, 43, 155-163.	0.3	57

#	Article	IF	Citations
235	Serum Mannan-Binding Lectin-Associated Serine Protease 2 Levels in Colorectal Cancer: Relation to Recurrence and Mortality. Clinical Cancer Research, 2005, 11, 1441-1446.	3.2	59
236	Mannose-Binding Lectin as a Predictor of Microalbuminuria in Type 1 Diabetes: An Inception Cohort Study. Diabetes, 2005, 54, 1523-1527.	0.3	111
237	Thyroid hormone increases mannan-binding lectin levels. European Journal of Endocrinology, 2005, 153, 643-649.	1.9	22
238	Mannan-binding lectin and procalcitonin measurement for prediction of postoperative infection. Critical Care, 2005, 9, R483.	2.5	28
239	Complement activation and diabetic vascular complications. Clinica Chimica Acta, 2005, 361, 10-19.	0.5	68
240	Plasma mannan-binding lectin levels and activity are increased in allergic patients. Journal of Allergy and Clinical Immunology, 2005, 116, 1381-1383.	1.5	24
241	The effects of GH and hormone replacement therapy on serum concentrations of mannan-binding lectin, surfactant protein D and vitamin D binding protein in Turner syndrome. European Journal of Endocrinology, 2004, 150, 355-362.	1.9	35
242	Mannose-binding Lectin-deficient Mice Are Susceptible to Infection with Staphylococcus aureus. Journal of Experimental Medicine, 2004, 199, 1379-1390.	4.2	256
243	L-ficolin Is a Pattern Recognition Molecule Specific for Acetyl Groups. Journal of Biological Chemistry, 2004, 279, 47513-47519.	1.6	173
244	Mannan-binding lectin modulates the response to HSV-2 infection. Clinical and Experimental Immunology, 2004, 138, 304-311.	1.1	77
245	Mannan-Binding Lectin and RSV Lower Respiratory Tract Infection Leading to Hospitalization in Children: A Case-Control Study from Soweto, South Africa. Scandinavian Journal of Immunology, 2004, 60, 184-188.	1.3	17
246	Increased activity of the mannanâ€binding lectin complement activation pathway in patients with colorectal cancer. Scandinavian Journal of Gastroenterology, 2004, 39, 674-679.	0.6	66
247	Mannan-binding lectin?a soluble pattern recognition molecule. Molecular Immunology, 2004, 41, 113-121.	1.0	122
248	Association Between Mannose-Binding Lectin and Vascular Complications in Type 1 Diabetes. Diabetes, 2004, 53, 1570-1576.	0.3	161
249	Mannanâ€Binding Lectin, Lâ€Ficolin and Hâ€Ficolin Selectively Binds to Different Bacteria. Scandinavian Journal of Immunology, 2004, 59, 625-625.	1.3	0
250	An Assay for Mannanâ€Binding Lectinâ€Associated Serine Protease 3, MASPâ€3. Scandinavian Journal of Immunology, 2004, 59, 630-630.	1.3	1
251	Association between Mannoseâ€Binding Lectin and Vascular Complications in Type 1 Diabetes. Scandinavian Journal of Immunology, 2004, 59, 613-613.	1.3	1
252	Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. Journal of Immunological Methods, 2003, 282, 159-167.	0.6	141

#	Article	IF	Citations
253	Umbilical Cord Mannan-Binding Lectin and Infections in Early Childhood. Scandinavian Journal of Immunology, 2003, 57, 167-172.	1.3	32
254	On the Site of C4 Deposition upon Complement Activation via the Mannan-Binding Lectin Pathway or the Classical Pathway. Scandinavian Journal of Immunology, 2003, 57, 556-561.	1.3	15
255	Murine serine proteases MASP-1 and MASP-3, components of the lectin pathway activation complex of complement, are encoded by a single structural gene. Genes and Immunity, 2003, 4, 374-384.	2.2	14
256	Studies on the mechanisms of allergen-induced activation of the classical and lectin pathways of complement. Molecular Immunology, 2003, 39, 839-846.	1.0	13
257	COLLECTINS ANDFICOLINS: Humoral Lectins of the Innate Immune Defense. Annual Review of Immunology, 2003, 21, 547-578.	9.5	700
258	Assays for the Mannanâ€Binding Lectin Pathway. Current Protocols in Immunology, 2003, 58, Unit 13.6.	3.6	11
259	Intensive Insulin Therapy Exerts Antiinflammatory Effects in Critically Ill Patients and Counteracts the Adverse Effect of Low Mannose-Binding Lectin Levels. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1082-1088.	1.8	466
260	Inherited Deficiency of Mannan-Binding Lectin–Associated Serine Protease 2. New England Journal of Medicine, 2003, 349, 554-560.	13.9	239
261	Elevated Levels of Mannan-Binding Lectin in Patients with Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4857-4861.	1.8	112
262	Expression of H-ficolin/Hakata antigen, mannose-binding lectin-associated serine protease (MASP)-1 and MASP-3 by human glioma cell line T98G. International Immunology, 2003, 15, 109-117.	1.8	45
263	Recombinant mannan-binding lectin (MBL) for therapy. Biochemical Society Transactions, 2003, 31, 763-767.	1.6	78
264	L-MBP Is Expressed in Epithelial Cells of Mouse Small Intestine. Journal of Immunology, 2002, 169, 6945-6950.	0.4	84
265	Assays for the Functional Activity of the Mannan-Binding Lectin Pathway of Complement Activation. Immunobiology, 2002, 205, 446-454.	0.8	101
266	The Mannan-Binding Lectin-Associated Serine Proteases (MASPs) and MAp19: Four Components of the Lectin Pathway Activation Complex Encoded by Two Genes. Immunobiology, 2002, 205, 455-466.	0.8	133
267	Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis. Microbes and Infection, 2002, 4, 773-784.	1.0	86
268	The mannan-binding lectin pathway of complement activation: biology and disease association. Molecular Immunology, 2001, 38, 133-149.	1.0	274
269	Recombinant expression of human mannan-binding lectin. International Immunopharmacology, 2001, 1, 677-687.	1.7	60
270	MASP-3 and Its Association with Distinct Complexes of the Mannan-Binding Lectin Complement Activation Pathway. Immunity, 2001, 15, 127-135.	6.6	357

#	Article	IF	CITATIONS
271	Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet, The, 2001, 358, 637-638.	6.3	252
272	Characterization and Quantification of Mouse Mannan-Binding Lectins (MBL-A and MBL-C) and Study of Acute Phase Responses. Scandinavian Journal of Immunology, 2001, 53, 489-497.	1.3	83
273	The mannan-binding-lectin pathway of the innate immune response. Current Opinion in Immunology, 2001, 13, 74-78.	2.4	100
274	The human gene for mannan-binding lectin-associated serine protease-2 (MASP-2), the effector component of the lectin route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2–3. Genes and Immunity, 2001, 2, 119-127.	2.2	42
275	An assay for the mannan-binding lectin pathway of complement activation. Journal of Immunological Methods, 2001, 257, 107-116.	0.6	199
276	Tail-Vein Injection of Mannan-Binding Lectin DNA Leads to High Expression Levels of Multimeric Protein in Liver. Molecular Therapy, 2001, 3, 867-874.	3.7	25
277	Role of the Classical Pathway of Complement Activation in Experimentally Induced Polymicrobial Peritonitis. Infection and Immunity, 2001, 69, 7304-7309.	1.0	35
278	Interaction Properties of Human Mannan-Binding Lectin (MBL)-Associated Serine Proteases-1 and -2, MBL-Associated Protein 19, and MBL. Journal of Immunology, 2001, 166, 5068-5077.	0.4	124
279	GH Strongly Affects Serum Concentrations of Mannan-Binding Lectin: Evidence for a New IGF-I Independent Immunomodulatory Effect of GH. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5383-5388.	1.8	46
280	Mannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophages. European Journal of Immunology, 2000, 30, 1706-1713.	1.6	27
281	Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. Journal of Immunological Methods, 2000, 241, 33-42.	0.6	313
282	Purification and Characterization of Two Mannan-Binding Lectins from Mouse Serum. Journal of Immunology, 2000, 164, 2610-2618.	0.4	100
283	Proteolytic Activities of Two Types of Mannose-Binding Lectin-Associated Serine Protease. Journal of Immunology, 2000, 165, 2637-2642.	0.4	288
284	Distinct Pathways of Mannan-Binding Lectin (MBL)- and C1-Complex Autoactivation Revealed by Reconstitution of MBL with Recombinant MBL-Associated Serine Protease-2. Journal of Immunology, 2000, 165, 2093-2100.	0.4	184
285	Interaction of C1q and Mannan-Binding Lectin (MBL) with C1r, C1s, MBL-Associated Serine Proteases 1 and 2, and the MBL-Associated Protein MAp19. Journal of Immunology, 2000, 165, 878-887.	0.4	99
286	Control of the classical and the MBL pathway of complement activation. Molecular Immunology, 2000, 37, 803-811.	1.0	132
287	Termination of IL-6-induced STAT activation is independent of receptor internalization but requires de novo protein synthesis. FEBS Letters, 2000, 470, 15-19.	1.3	25
288	Assignment footref rid="foot01" sup 1 footref	0.6	22

#	Article	IF	Citations
289	Mannan-Binding Lectin Deficiency is Associated with Unexplained Recurrent Miscarriage. Scandinavian Journal of Immunology, 1999, 49, 193-196.	1.3	103
290	Mannose-binding lectin and meningococcal disease. Lancet, The, 1999, 354, 338.	6.3	2
291	Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structural gene. Journal of Immunology, 1999, 162, 3481-90.	0.4	152
292	The rat and mouse homologues of MASP-2 and MAp19, components of the lectin activation pathway of complement. Journal of Immunology, 1999, 163, 6848-59.	0.4	27
293	Reconstitution of Opsonizing Activity by Infusion of Mannanâ€Binding Lectin (MBL) to MBLâ€Deficient Humans. Scandinavian Journal of Immunology, 1998, 48, 116-123.	1.3	127
294	Cloning and sequencing of a cDNA encoding chicken mannan-binding lectin (MBL) and comparison with mammalian analogues. Immunology, 1998, 93, 421-430.	2.0	49
295	MASP-2, the C3 Convertase Generating Protease of the MBLectin Complement Activating Pathway. Immunobiology, 1998, 199, 348-357.	0.8	37
296	Plasma mannan-binding lectin kills microorganisms. Biomedicine and Pharmacotherapy, 1998, 52, 45.	2.5	0
297	Constitutive internalization and association with adaptor protein-2 of the interleukin-6 signal transducer gp130. FEBS Letters, 1998, 441, 231-234.	1.3	41
298	Serum levels, ontogeny and heritability of chicken mannanâ€binding lectin (MBL). Immunology, 1998, 94, 587-593.	2.0	40
299	Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer $\hat{E}^{1}/4$ s disease. NeuroReport, 1998, 9, 1491-1495.	0.6	31
300	A Rainbow Trout Lectin with Multimeric Structure. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1997, 116, 385-390.	0.7	50
301	A second serine protease associated with mannan-binding lectin that activates complement. Nature, 1997, 386, 506-510.	13.7	799
302	The effect of mannan-binding lectin on opsonophagocytosis of Neisseria meningitidis. Immunopharmacology, 1997, 38, 93-99.	2.0	21
303	Mannan-binding lectin serum concentrations in HIV-infected patients are influenced by the stage of disease. Immunology Letters, 1997, 58, 171-175.	1.1	39
304	Improvements on the purification of mannan-binding lectin and demonstration of its Ca2+-independent association with a C1s-like serine protease. Biochemical Journal, 1996, 319, 329-332.	1.7	101
305	Glycopeptide mimics of mammalian Man9GlcNAc2. Ligand binding to mannan-binding proteins (MBPs). Bioorganic and Medicinal Chemistry, 1996, 4, 1881-1899.	1.4	9
306	Human Autoantibodies Against C1q: Lack of Crossâ€Reactivity with the Collectins Mannanâ€Binding Protein, Lung Surfactant Protein A and Bovine Conglutinin. Scandinavian Journal of Immunology, 1996, 43, 314-320.	1.3	21

#	Article	IF	Citations
307	Use of Factorial Experimental Design to Delineate the Strong Calcium- and pH-Dependent Changes in Binding of Human Surfactant Protein-A to Neutral Glycosphingolipids-A Model for Studies of Protein-Carbohydrate Interactions. Analytical Biochemistry, 1995, 225, 305-314.	1.1	16
308	Ontogeny of human mannan-binding protein, a lectin of the innate immune system. Pediatric Allergy and Immunology, 1995, 6, 20-23.	1.1	74
309	Collectin in a non-mammalian species: isolation and characterization of mannan-binding protein (MBP) from chicken serum. Glycobiology, 1995, 5, 553-561.	1.3	43
310	Isolation of a pentraxin-like protein from rainbow trout serum. Developmental and Comparative Immunology, 1995, 19, 305-314.	1.0	36
311	Mannanâ€binding protein and complement dependent opsonization in alcoholic cirrhosis. Liver, 1995, 15, 39-44.	0.1	17
312	Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. Journal of Immunology, 1995, 155, 3013-20.	0.4	544
313	A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics, 1994, 40, 37-44.	1.2	483
314	Recognition of the major cell surface glycoconjugates of Leishmania parasites by the human serum mannan-binding protein. Molecular and Biochemical Parasitology, 1994, 66, 319-328.	0.5	91
315	Purification and Characterization of Mannan-Binding Protein from Mouse Serum. Scandinavian Journal of Immunology, 1994, 39, 202-208.	1.3	27
316	Mannan-Binding Protein and Bovine Conglutinin Mediate Enhancement of Herpes Simplex Virus Type 2 Infection in Mice. Scandinavian Journal of Immunology, 1994, 39, 439-445.	1.3	44
317	Binding of human collectins (SP-A and MBP) to influenza virus. Biochemical Journal, 1994, 304, 455-461.	1.7	87
318	Mannan-binding protein levels in human amniotic fluid during gestation and its interaction with collectin receptor from amnion cells. Immunology, 1994, 82, 439-44.	2.0	45
319	Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c. Immunology, 1994, 81, 648-54.	2.0	28
320	A Low Serum Concentration of Mannan-Binding Protein is Not Associated with Serogroup B or C Meningococcal Disease. Scandinavian Journal of Immunology, 1993, 37, 468-470.	1.3	41
321	Structural similarity between lung surfactant protein D and conglutinin. Two distinct, C-type lectins containing collagen-like sequences. FEBS Journal, 1993, 215, 793-799.	0.2	62
322	Pollen grains bind to lung alveolar type II cells (A549) via lung surfactant protein A (SP-A). Bioscience Reports, 1993, 13, 79-90.	1.1	99
323	Studies on the carbohydrate-binding characteristics of human pulmonary surfactant-associated protein A and comparison with two other collectins: mannan-binding protein and conglutinin. Biochemical Journal, 1993, 293, 873-878.	1.7	95
324	The cDNA cloning of conglutinin and identification of liver as a primary site of synthesis of conglutinin in members of the Bovidae. Biochemical Journal, 1993, 292, 157-162.	1.7	42

#	Article	lF	CITATIONS
325	Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. Aids, 1993, 7, 1307-1314.	1.0	124
326	Mannan-binding protein, a complement activating animal lectin. Immunopharmacology, 1992, 24, 91-99.	2.0	47
327	DIALLELIC POLYMORPHISM MAY EXPLAIN VARIATIONS OF THE BLOOD CONCENTRATION OF MANNAN-BINDING PROTEIN IN ESKIMOS, BUT NOT IN BLACK AFRICANS. International Journal of Immunogenetics, 1992, 19, 403-412.	1.2	126
328	Interaction of C1q receptor with lung surfactant protein A. European Journal of Immunology, 1992, 22, 1437-1445.	1.6	139
329	In Vivo and In Vitro Antibacterial Activity of Conglutinin, a Mammalian Plasma Lectin. Scandinavian Journal of Immunology, 1990, 31, 453-460.	1.3	81
330	Human leukocyte C1q receptor binds other soluble proteins with collagen domains Journal of Experimental Medicine, 1990, 172, 955-959.	4.2	279
331	Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q. Journal of Immunology, 1990, 144, 2287-94.	0.4	265
332	ASSOCIATION OF LOW LEVELS OF MANNAN-BINDING PROTEIN WITH A COMMON DEFECT OF OPSONISATION. Lancet, The, 1989, 334, 1236-1239.	6.3	464
333	Structures and functions associated with the group of mammalian lectins containing collagen-like sequences. FEBS Letters, 1989, 250, 78-84.	1.3	185
334	Oligosaccharide-mediated interactions of the envelope glycoprotein gp120 of HIV-1 that are independent of CD4 recognition. Aids, 1989, 3, 793-798.	1.0	84
335	Neoglycolipids as probes of oligosaccharide recognition by recombinant and natural mannose-binding proteins of the rat and man. Biochemical Journal, 1989, 262, 131-138.	1.7	112
336	A library of Oligosaccharide Probes (Neoglycolipids) from N-Glycosylated Proteins Reveals That Conglutinin Binds to Certain Complex-type as Well as High Mannose-type Oligosaccharide Chains. Journal of Biological Chemistry, 1989, 264, 13834-13839.	1.6	84
337	A library of oligosaccharide probes (neoglycolipids) from N-glycosylated proteins reveals that conglutinin binds to certain complex-type as well as high mannose-type oligosaccharide chains. Journal of Biological Chemistry, 1989, 264, 13834-9.	1.6	80
338	Demonstration in Human Plasma of a Lectin Activity Analogous to that of Bovine Conglutinin. Scandinavian Journal of Immunology, 1987, 26, 355-361.	1.3	25
339	Characterization of a Lectin in Human Plasma Analogous to Bovine Conglutinin. Scandinavian Journal of Immunology, 1987, 26, 461-468.	1.3	25
340	Human conglutinin-like protein. Bioscience Reports, 1985, 5, 901-905.	1.1	10
341	Analysis of Activity of Mannan-Binding Lectin, an Initiator of the Lectin Pathway of the Complement System., 0,, 133-137.		O
342	Low levels of the innate immune system proteins <scp>MASP</scp> â€2 and <scp>MAp44</scp> in patients with common variable immunodeficiency. Scandinavian Journal of Immunology, 0, , .	1.3	1